BPMC

Blueprint Medicines Corporation

90.96 USD
+0.16 (+0.18%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Blueprint Medicines Corporation stock is up 18.65% since 30 days ago. The next earnings date is May 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 77.78% of the previous 8 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 10 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Feb 19:35 20 Dec, 2024 130.00 CALL 200 0
16 Feb 14:40 19 Jul, 2024 100.00 CALL 36 3585
16 Feb 15:21 15 Mar, 2024 100.00 CALL 288 101
23 Feb 15:00 19 Apr, 2024 100.00 CALL 284 585
26 Feb 16:03 17 Jan, 2025 100.00 CALL 20 0
27 Feb 15:57 17 Jan, 2025 140.00 CALL 200 0
28 Feb 18:36 19 Apr, 2024 75.00 CALL 15 52
04 Mar 14:34 17 Jan, 2025 100.00 CALL 20 20
04 Mar 15:10 15 Mar, 2024 90.00 CALL 50 442
04 Mar 15:39 20 Dec, 2024 80.00 CALL 20 152

About Blueprint Medicines Corporation

Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.

  • Needham
    Mon Feb 26, 06:51
    buy
    confirm
  • JP Morgan
    Fri Feb 16, 14:34
    buy
    confirm
  • Citigroup
    Fri Feb 16, 12:10
    sell
    confirm
  • Barclays
    Tue Feb 13, 09:10
    hold
    confirm